INHIBITION OF PLATELET-AGGREGATION BY A NEW AGENT, TICLOPIDINE
- 1 January 1979
- journal article
- research article
- Vol. 40 (3) , 542-550
Abstract
The effect of ticlopidine, 5-(2-chlorobenzyl)-4, 5, 6, 7-tetrahydro[3,2-C]pyridine hydrochloride on platelet aggregation was studied in the rat. Ticlopidine was a potent, long-lasting inhibitor of platelet aggregation. It inhibited the aggregation induced by any of ADP, collagen, thrombin, arachidonic acid and prostaglandin endoperoxides and/or thromboxane A2-like substance. Ticlopidine was effective at doses as low as 30 mg/kg when orally given to rats, and the effect lasted as long as the life span of the circulating platelets (half time: about 48 h). Ticlopidine also inhibited nucleotide release from and prostaglandin synthesis in the platelets, but did not significantly affect platelet adhesiveness to glass, platelet factor 3 availability and clot retraction.This publication has 5 references indexed in Scilit:
- Anti-thrombotic action of ticlopidine, a new platelet aggregation inhibitorThrombosis Research, 1978
- Persistence of thromboxane A2-like material and platelet release-inducing activity in plasma.Journal of Clinical Investigation, 1976
- Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxidesNature, 1976
- Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human plateletsBiochemical and Biophysical Research Communications, 1976
- Studies on Platelet Factor-3 AvailabilityBritish Journal of Haematology, 1965